Alzamend Neuro, Inc. (ALZN) stock
ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 10, 2026Score 4/30
$1.04−0.09 (-7.96%)
Close on Nov 18, 2026Market cap $5.02MP/E –Yield –
Alzamend Neuro r&d expenses
Research and development expenses are spending on new products and technology.
Alzamend Neuro's R&D Expenses for the twelve months ending Jul 31, 2026 was $2.97M. For fiscal 2026 it was $3.63M, up 156.5% from the year before. The highest annual figure on record is $7.45M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | $3.63M | +156.5% |
| FY2025 | Apr 30, 2025 | $1.41M | -78.1% |
| FY2024 | Apr 30, 2024 | $6.46M | -13.3% |
| FY2023 | Apr 30, 2023 | $7.45M | +43.2% |
| FY2022 | Apr 30, 2022 | $5.20M | +296.8% |
| FY2021 | Apr 30, 2021 | $1.31M | +22.6% |
| FY2020 | Apr 30, 2020 | $1.07M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | $1.09M | -37.6% |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | $434.01K | +110.1% |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | $1.28M | +597.1% |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | $176.28K | -90.8% |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | $1.74M | -12.8% |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | $206.57K | -91.3% |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | $183.43K | -88.9% |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | $1.91M | -33.9% |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | $2.00M | +30.3% |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | $2.37M | +72.0% |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | $1.65M | -0.8% |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | $2.89M | +230.7% |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | $1.53M | -12.4% |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | $1.38M | +50.1% |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | $1.66M | +467.6% |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | $873.65K | +272.9% |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | $1.75M | +268.5% |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | $916.41K | +196.7% |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | $292.70K | – |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | $234.26K | – |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | $474.91K | – |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | $308.85K | – |
See a number that looks wrong?